87 phenotypes from 6 alleles in 14 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Prf1m1Btlr/Prf1m1Btlr C57BL/6J-Prf1m1Btlr	increased susceptibility to Herpesvirales infection	J:216044
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:216044
Prf1tm1.1(KOMP)Vlcg/Prf1tm1.1(KOMP)Vlcg C57BL/6N-Prf1tm1.1(KOMP)Vlcg/Ucd	decreased mean corpuscular hemoglobin concentration	J:211773
Prf1tm1Clrk/Prf1tm1Clrk C.129S7(B6)-Prf1tm1Clrk	abnormal cytokine secretion	J:71576
	normal immune system phenotype	J:71576
	increased activated T cell number	J:71576
	increased interferon-gamma secretion	J:71576
	increased susceptibility to Riboviria infection	J:71576
	increased tumor necrosis factor secretion	J:71576
Prf1tm1Clrk/Prf1tm1Clrk involves: 129S7/SvEvBrd * BALB/c * NOD	decreased susceptibility to autoimmune diabetes	J:64051
Prf1tm1Clrk/Prf1tm1Clrk involves: 129S7/SvEvBrd * C57BL/6	decreased cytotoxic T cell cytolysis	J:21531
	normal immune system phenotype	J:21531
	increased susceptibility to Riboviria infection	J:21531
Prf1tm1Geno/Prf1tm1Geno involves: C57BL/6	no abnormal phenotype detected	J:142654
Prf1tm1Sdz/Prf1+ A.B6-Prf1tm1Sdz	impaired natural killer cell mediated cytotoxicity	J:211842
	increased incidence of induced tumors	J:211842
Prf1tm1Sdz/Prf1+ NOD.B6-Prf1tm1Sdz	decreased susceptibility to autoimmune diabetes	J:43468
	insulitis	J:43468
	periinsulitis	J:43468
Prf1tm1Sdz/Prf1tm1Sdz A.B6-Prf1tm1Sdz	impaired natural killer cell mediated cytotoxicity	J:211842
	increased incidence of induced tumors	J:211842
Prf1tm1Sdz/Prf1tm1Sdz C57BL/6-Prf1tm1Sdz	abnormal female reproductive system physiology	J:59892
	abnormal inflammatory response	J:17986
	abnormal leukocyte physiology	J:17986
	abnormal NK cell physiology	J:113213
	decreased cytotoxic T cell cytolysis	J:17986
	decreased tumor latency	J:77491
	impaired natural killer cell mediated cytotoxicity	J:17986
	increased B cell derived lymphoma incidence	J:77491
	increased interleukin-10 secretion	J:123934
	increased lymphoma incidence	J:77491
	increased susceptibility to bacterial infection	J:123934
	increased susceptibility to induced morbidity/mortality	J:113213
	increased susceptibility to infection	J:17986
	increased susceptibility to parasitic infection	J:81397
	increased susceptibility to Riboviria infection	J:17986
	premature death	J:77491
Prf1tm1Sdz/Prf1tm1Sdz C57BL/6-Prf1tm1Sdz/J	abnormal behavior	J:120427
	abnormal body temperature homeostasis	J:92260
	abnormal brain meninges morphology	J:92260
	abnormal circulating cytokine level	J:92260
	abnormal cytotoxic T cell physiology	J:193137
	abnormal lymph node morphology	J:92260
	abnormal lymphocyte physiology	J:120427
	abnormal macrophage activation involved in immune response	J:92260
	abnormal spleen white pulp morphology	J:92260
	abnormal T cell activation	J:92260
	normal behavior/neurological phenotype	J:120427
	brain inflammation	J:92260, J:120427
	CNS inflammation	J:120427
	decreased body temperature	J:193137
	decreased bone marrow cell number	J:92260
	decreased circulating fibrinogen level	J:92260
	decreased cytotoxic T cell cytolysis	J:193137
	decreased erythrocyte cell number	J:193137
	decreased interferon-gamma secretion	J:92260
	decreased leukocyte cell number	J:193137
	decreased locomotor activity	J:92260
	decreased neutrophil cell number	J:193137
	decreased NK cell degranulation	J:193137
	demyelination	J:120427
	hunched posture	J:92260, J:193137
	normal immune system phenotype	J:120427
	increased circulating aspartate transaminase level	J:193137
	increased circulating interferon-alpha level	J:92260
	increased circulating interferon-gamma level	J:92260, J:193137
	increased circulating interleukin-1 beta level	J:193137
	increased circulating interleukin-6 level	J:92260, J:193137
	increased circulating interleukin-10 level	J:92260
	increased circulating interleukin-18 level	J:92260
	increased circulating lactate dehydrogenase level	J:193137
	increased circulating triglyceride level	J:92260
	increased circulating tumor necrosis factor level	J:92260, J:193137
	increased spleen red pulp amount	J:92260
	increased susceptibility to Picornaviridae infection	J:120427
	increased susceptibility to Riboviria infection	J:92260, J:193137
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:92260
	increased susceptibility to viral infection induced morbidity/mortality	J:193137
	lethargy	J:193137
	liver inflammation	J:92260
	lymph node inflammation	J:92260
	lymph node necrosis	J:92260
	pancytopenia	J:92260, J:193137
	ruffled hair	J:92260
	thrombocytopenia	J:193137
	weight loss	J:193137
Prf1tm1Sdz/Prf1tm1Sdz C.B6-Prf1tm1Sdz	abnormal tumor morphology	J:77491
	increased lung adenocarcinoma incidence	J:77491
	increased lymphoma incidence	J:77491
	increased sarcoma incidence	J:77491
	increased T cell derived lymphoma incidence	J:77491
	increased tumor latency	J:77491
Prf1tm1Sdz/Prf1tm1Sdz involves: BALB/c * C57BL/6	impaired natural killer cell mediated cytotoxicity	J:73948
Prf1tm1Sdz/Prf1tm1Sdz NOD.B6-Prf1tm1Sdz	abnormal circulating glucose level	J:43468
	decreased pancreatic beta cell number	J:43468
	decreased susceptibility to autoimmune diabetes	J:43468
	increased physiological sensitivity to xenobiotic	J:43468
	insulitis	J:43468
	periinsulitis	J:43468
Prf1tm1Tsc/Prf1+ involves: 129S2/SvPas	decreased cytotoxic T cell cytolysis	J:21731
	impaired natural killer cell mediated cytotoxicity	J:21731
Prf1tm1Tsc/Prf1tm1Tsc 129X1.129S2-Prf1tm1Tsc	abnormal NK cell physiology	J:126114
	decreased T cell apoptosis	J:126114
	increased susceptibility to induced morbidity/mortality	J:126114
	increased tumor growth/size	J:126114
Prf1tm1Tsc/Prf1tm1Tsc involves: 129S2/SvPas	decreased circulating alanine transaminase level	J:50903
	decreased cytotoxic T cell cytolysis	J:21731
	decreased susceptibility to bacterial infection	J:50903
	impaired natural killer cell mediated cytotoxicity	J:21731